Videos
Day 1
Click one or more tumour names to filter results
Vanderbilt University Medical Center
Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker
Netherlands Cancer Institute
Systemic Therapy, Gastrectomy and CRS/HIPEC vs Systemic Therapy Alone for Gastric Cancer with Limited Peritoneal Dissemination: Results of the Randomised PERISCOPE II Trial.
University of Texas MD Anderson Cancer Center
LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma
Dr. B. R. Ambedkar Institute Rotary Cancer Hospital
Low Dose Pembrolizumab in Addition to Neoadjuvant Anthracycline and Taxane in Triple Negative Breast Cancer: A Randomized Controlled Trial
The Institute of Cancer Research
Randomized Comparison of upfront Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial
University Hospital Essen
Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
Charite-University Medicine Berlin
Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomised POTOMAC trial
University of California
Phase 1 study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
University Medical Center Hamburg - Eppendorf
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma – Interim Analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)
Fred Hutchinson Cancer Center
Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
UNSW Sydney
Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
Day 2
Click one or more tumour names to filter results
Institut Curie
Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2− BC: Preliminary Analysis of the SOLTI-RIBOLARIS Trial
MD Anderson Cancer Center Madrid
DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.
Dana-Farber Cancer Institute
Randomised phase 3 trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
David Geffen School of Medicine at UCLA
Prospective Randomized Phase 2 trial of 177Lutetium-PSMA therapy Neoadjuvant to Stereotactic Ablative Radiotherapy for recurrent Oligo-Metastatic Hormone-Sensitive Prostate Cancer (LUNAR NCT05496959)
Integrated Cancer Centre Ghent
Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study
The University of Western Australia
Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma – A phase 3 Randomised trial
MD Anderson Cancer Center
LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)
IFOM
Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: final results of the PEGASUS trial.
University Hospital Frankfurt
Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment
Beijing Cancer Hospital
Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression
The Royal Marsden Hospital
SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)
The Chinese University of Hong Kong
Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
Shanghai Jiao Tong University School of Medicine
Disitamab Vedotin plus Tislelizumab as Nephron-Sparing Therapy for High-Risk Upper Tract Urothelial Carcinoma: The Phase II DISTINCT-I Trial
Day 3
Click one or more tumour names to filter results
Hamamatsu Medical Center
Prospective observational study of brigatinib after alectinib in ALK-positive, non-small cell lung cancer: efficacy and biomarker analyses from Cohort A of the WJOG11919L/ABRAID trial
Hôpital Pitié-Salpêtrière
FOLFOX plus PANITUMUMAB (Pmab) according to a “stop-and-go” strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC). Results of the FFCD 1605 – OPTIPRIME phase II trial.
IRCCS San Raffaele Hospital
Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results
University of British Columbia
A randomized phase 2 study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21
Institut Curie
PLUME: A single-arm phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM)
Princess Margaret Cancer Center
A phase 2 study of Avelumab in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based chemotherapy or Progressed On or After Platinum-based Chemotherapy (ALPACA)
University of Leicester
3D-response and multiomic correlates of Niraparib in relapsed mesothelioma: NERO, a randomised clinical trial in patients with relapsed mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)
UPMC Hillman Cancer Center
Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase 3 STELLAR-303 study
Princess Margaret Cancer Centre
Enucleation prevention and vision preservation in primary uveal melanoma (UM): preliminary results from a phase 2 study of neoadjuvant darovasertib.
Weill Cornell Medicine
Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Moffitt Cancer Center
1034MO
Long-term Follow-up of Peptide Receptor Radionuclide Therapy (PRRT)-Naïve Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treated with Targeted Alpha Therapy 212Pb-DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial
1032O
Efficacy and safety of targeted alpha therapy 212Pb-DOTAMTATE in patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) previously treated with peptide receptor radionuclide therapy (PRRT): Results of a phase II study
IRCCS Ospedale San Raffaele
Results of a randomized phase 3 trial of short-course versus long-course pre-operative chemotherapy for stage I-III pancreatic ductal adenocarcinoma (PDAC)
University of Texas MD Anderson Cancer Center
1601O
3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801
1600O
Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial
Sun Yat-Sen University
Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study
LungenClinic Grosshansdorf
Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study
Erasmus MC
Overall survival with first versus second line use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer
Peter MacCallum Cancer Centre
ctDNA-Guided Adjuvant Chemotherapy De-Escalation in Stage III Colon Cancer: Primary Analysis of the ctDNA-Negative Cohort from the Randomized AGITG DYNAMIC-III Trial (Intergroup Study of AGITG and CCTG)
Nationalen Centrum für Tumorerkrankungen
IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary Phase 3 results (IOB-013/KN-D18)
University of Miami Miller School of Medicine
Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Peter MacCallum Cancer Centre
Analysis of second primary cutaneous squamous cell carcinoma (CSCC) tumors (SPTs) reported during the C-POST trial, a randomized phase III study of adjuvant cemiplimab vs placebo (pbo) for high-risk CSCC
Geffen School of Medicine at UCLA
IMbrave152/SKYSCRAPER-14: A phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)
